Method of preparing cross-linked bioactive hydrogel matrices
View Patent ↗The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight component are each selected from the group consisting of polyglycans and polypeptides. This stabilized hydrogel matrix may be prepared as bioactive gels, pastes, slurries, cell attachment scaffolds for implantable medical devices, and casting or binding materials suitable for the construction of medical devices. The intrinsic bioactivity of the hydrogel matrix makes it useful as a gel or paste in multiple applications, including as a cell attachment scaffold that promotes wound healing around an implanted device, as gels and pastes for induction of localized vasculogenesis, wound healing, tissue repair, and regeneration, as a wound adhesive, and for tissue bulking.
1. A method of preparing a cross-linked bioactive hydrogel matrix, comprising:
providing a mixture of a polyglycan, a polypeptide, and at least one enhancing agent selected from the group consisting of polar amino acids, intact collagen, divalent cation chelators, and combinations thereof; and
reacting the polyglycan with the polypeptide under conditions sufficient to covalently cross-link the polyglycan to the polypeptide.
2. The method of claim 1 , wherein the polyglycan is a polysaccharide or a sulfated polysaccharide.
3. The method of claim 2 , wherein the polyglycan is selected from the group consisting of dextran, heparan, heparin, hyaluronic acid, alginate, agarose, carageenan, amylopectin, amylose, glycogen, starch, cellulose, chitin, heparan sulfate, chondroitin sulfate, dextran sulfate, dermatan sulfate, and keratan sulfate.
4. The method of claim 2 , wherein the polysaccharide is selected from the group consisting of glycosaminoglycans and glucosaminoglycans.
5. The method of claim 1 , wherein the polyglycan has a molecular weight of about 2,000 to about 8,000,000 Da.
6. The method of claim 1 , wherein the polypeptide is a tissue-derived polypeptide.
7. The method of claim 6 , wherein the tissue-derived polypeptide is selected from the group consisting of collagens, gelatins, keratin, decorin, aggrecan, glycoproteins, laminin, nidogen, fibulin, and fibrillin.
8. The method of claim 6 , wherein the polypeptide is a tissue-derived polypeptide derived from extracts of tissue, wherein the tissue is selected from the group consisting of submucosal tissues, arteries, vocal chords, pleura, trachea, bronchi, pulmonary alveolar septa, ligaments, auricular cartilage, abdominal fascia, liver, kidney, neurilemma, arachnoid, dura mater, and pia mater.
9. The method of claim 1 , wherein the polypeptide has a molecular weight of about 3,000 to about 3,000,000 Da.
10. The method of claim 1 , wherein the polyglycan is dextran and the polypeptide is gelatin.
11. The method of claim 1 , wherein the at least one enhancing agent comprises at least one polar amino acid selected from the group consisting of tyrosine, cysteine, serine, threonine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, lysine, histidine, and mixtures thereof.
12. The method of claim 1 , wherein the at least one enhancing agent comprises ethylenediaminetetraacetic acid or a salt thereof.
13. The method of claim 1 , further comprising, prior to said reacting step, chemically modifying at least one of the polyglycan and the polypeptide to form reactive sites thereon capable of participating in covalent bonding.
14. The method of claim 13 , wherein said modifying step comprises oxidizing at least one of the polyglycan and the polypeptide.
15. The method of claim 13 , wherein said modifying step comprises treating at least one of the polyglycan and the polypeptide with a salt of periodic acid.
16. The method of claim 13 , wherein the polyglycan is dextran, and said modifying step comprises oxidizing the dextran to form reactive sites thereon.
17. The method of claim 16 , wherein the reactive sites are aldehyde or ketone groups.
18. The method of claim 1 , wherein said reacting step comprises reacting the polyglycan and the polypeptide in the presence of at least one bifunctional crosslinker.
19. The method of claim 18 , wherein the cross-linker is selected from the group consisting of glutaraldehyde, epoxides, oxidized dextran, p-azidobenzoyl hydrazide, N-[α-maleimidoacetoxy]succinimide ester, p-azidophenyl glyoxal monohydrate, bis-[β-(4-azidosalicylamido)ethyl]disulfide, bis-[sulfosuccinimidyl]suberate, dithiobis[succinimidyl]propionate, disuccinimidyl suberate, and 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride.
20. The method of claim 1 , wherein said reacting comprises reacting functional groups on the polyglycan with functional groups on the polypeptide.
21. The method of claim 1 , wherein said covalently cross-linking of the polyglycan to the polypeptide occurs through the formation of Shiff's base links.
22. A method of preparing a cross-linked bioactive hydrogel matrix, comprising:
providing a mixture of a dextran, a gelatin, and at least one enhancing agent selected from the group consisting of polar amino acids, intact collagen, divalent cation chelators, and combinations thereof; and
reacting the dextran with the gelatin under conditions sufficient to covalently cross-link the dextran to the gelatin.
23. The method of claim 22 , wherein the at least one enhancing agent comprises at least one polar amino acid selected from the group consisting of tyrosine, cysteine, serine, threonine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, lysine, histidine, and mixtures thereof.
24. The method of claim 22 , wherein the at least one enhancing agent comprises ethylenediaminetetraacetic acid or a salt thereof.
25. The method of claim 22 , further comprising, prior to said reacting step, chemically modifying at least one of the dextran and the gelatin to form reactive sites thereon capable of participating in covalent bonding.
26. The method of claim 25 , wherein said modifying step comprises oxidizing at least one of the dextran and the gelatin.
27. The method of claim 25 , wherein said modifying step comprises treating at least one of the dextran and the gelatin with a salt of periodic acid.
28. The method of claim 25 , wherein said modifying step comprises oxidizing the dextran to form reactive sites thereon.
29. The method of claim 28 , wherein the reactive sites are aldehyde or ketone groups.
30. The method of claim 22 , wherein said reacting step comprises reacting the dextran and the gelatin in the presence of at least one bifunctional crosslinker.
31. The method of claim 30 , wherein the cross-linker is selected from the group consisting of glutaraldehyde, epoxides, oxidized dextran, p-azidobenzoyl hydrazide, N-[α-maleimidoacetoxy]succinimide ester, p-azidophenyl glyoxal monohydrate, bis-[β-(4-azidosalicylamido)ethyl]disulfide, bis-[sulfosuccinimidyl]suberate, dithiobis[succinimidyl]propionate, disuccinimidyl suberate, and 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride.
32. The method of claim 22 , wherein said reacting comprises reacting functional groups on the dextran with functional groups on the gelatin.
33. The method of claim 22 , wherein said covalently cross-linking of the dextran to the gelatin occurs through the formation of Shiff's base links.
34. A method of preparing a cross-linked bioactive hydrogel matrix, comprising:
providing a mixture of a polyglycan, a polypeptide, and at least one enhancing agent selected from the group consisting of polar amino acids, divalent cation chelators, and combinations thereof, wherein the polyglycan is modified so as to have reactive sites thereon capable of participating in covalent bonding; and
reacting the modified polyglycan with the polypeptide under conditions sufficient to covalently cross-link the polyglycan to the polypeptide.
35. The method of claim 34 , wherein the at least one enhancing agent comprises at least one polar amino acid selected from the group consisting of tyrosine, cysteine, serine, threonine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, lysine, histidine, and mixtures thereof.
36. The method of claim 34 , wherein the at least one enhancing agent comprises ethylenediaminetetraacetic acid or a salt thereof.
37. The method of claim 34 , wherein the polyglycan is a polysaccharide or a sulfated polysaccharide.
38. The method of claim 37 , wherein the polyglycan is selected from the group consisting of dextran, heparan, heparin, hyaluronic acid, alginate, agarose, carageenan, amylopectin, amylose, glycogen, starch, cellulose, chitin, heparan sulfate, chondroitin sulfate, dextran sulfate, dermatan sulfate, and keratan sulfate.
39. The method of claim 34 , wherein the polypeptide is a tissue-derived polypeptide.
40. The method of claim 39 , wherein the tissue-derived polypeptide is selected from the group consisting of collagens, gelatins, keratin, decorin, aggrecan, glycoproteins, laminin, nidogen, fibulin, and fibrillin.
41. The method of claim 39 , wherein the tissue-derived polypeptide is derived from extracts of tissue selected from the group consisting of submucosal tissues, arteries, vocal chords, pleura, trachea, bronchi, pulmonary alveolar septa, ligaments, auricular cartilage, abdominal fascia, liver, kidney, neurilemma, arachnoid, dura mater, and pia mater.
42. The method of claim 34 , wherein the polyglycan is dextran and the polypeptide is gelatin.